Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferumoxytol,Gadobutrol
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Lipella Pharmaceuticals | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 13, 2023
Lead Product(s) : Ferumoxytol,Gadobutrol
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Lipella Pharmaceuticals | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Covis Pharma
Deal Size : $647.0 million
Deal Type : Acquisition
Covis Group Completes Acquisition of AMAG Pharmaceuticals
Details : The acquisition adds AMAG's key products Feraheme®, Makena® and Ciraparantag to Covis' pipeline as it carries out its mission of expanding patient access to much needed therapies.
Product Name : Feraheme
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : $647.0 million
November 16, 2020
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Covis Pharma
Deal Size : $647.0 million
Deal Type : Acquisition
Lead Product(s) : Ferumoxytol,Sodium Chloride,Ferrous Sulfate,Ascorbic Acid
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : Ferumoxytol,Sodium Chloride,Ferrous Sulfate,Ascorbic Acid
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Covis Pharma
Deal Size : $647.0 million
Deal Type : Acquisition
Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals
Details : With this deal, Covis gains access to AMAG’s two commercial therapies, Makena, indicated for women with risk of preterm birth in singleton pregnancies and Feraheme indicated treat iron deficiency anaemia in CKD patients and for whom oral iron is not su...
Product Name : Feraheme
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : $647.0 million
January 10, 2020
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Covis Pharma
Deal Size : $647.0 million
Deal Type : Acquisition
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 19, 2019
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 06, 2019
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 28, 2019
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferumoxytol,Ascorbic Acid,Ferrous Sulfate,Sodium Chloride
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 17, 2018
Lead Product(s) : Ferumoxytol,Ascorbic Acid,Ferrous Sulfate,Sodium Chloride
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 05, 2018
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 08, 2018
Lead Product(s) : Ferumoxytol,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable